A meta-study of randomized controlled trials (RCTs) has found that there was a remarkable association between the combination therapy of insulin with sodium-glucose cotransporter (SGLT) inhibitors and the decrease in HbA1c of -0.39% (95% CI, -0.43 to -0.36) as well as body weight loss of -3.47% (95% CI, -3.78 to -3.16), suggesting the beneficial effects of this combination in T1D treatment. Here, INS is linked to type 1 diabetes mellitus.